Background and Purpose-Women are more likely to have a worse outcome after an acute stroke than men. Some studies have suggested that women also benefit less from intravenous thrombolysis after an acute ischemic stroke, but others found no sex differences in safety and efficacy. We aimed to evaluate differences in 3-month outcome between sexes in intravenous tissue-type plasminogen activator-treated patients registered in the Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Register. Methods-A total of 45 079 patients treated with intravenous alteplase were recorded from 2002 to 2011. Main outcome measures were symptomatic intracerebral hemorrhage, functional independence (modified Rankin Scale score, 0-2), and mortality at 3 months. Results-Among 25 777 (57.2%) men and 19 302 (42.8%) women, we found no difference in the rate of symptomatic intracerebral hemorrhage (P=0.13), a significantly higher likelihood of functional independence at 3 months in men (P<0.0001) and a higher mortality in women when compared with men (P<0.00001). After adjustment for confounding variables, we did not observe any difference between sexes in functional outcome (odds ratio, 1.03; 95% confidence interval, 0.97-1.09; P=0.39), whereas male sex was related to a higher risk of mortality (odds ratio, 
T he effect of sex on various aspects of stroke, from epidemiology to prognosis, through risk factor profile, pathogenesis, clinical presentation, and response to treatment has been extensively investigated in the past years. 1 Longitudinal studies based on stroke registries suggested that women are more likely than men to have a stroke 2 because of their higher life expectancy associated with the fact that stroke incidence increases exponentially with age. In addition, the natural course of stroke is worse in women having a higher probability to be functionally dependent and institutionalized. 1, [3] [4] [5] More recently, the interest of researchers has also been focused on the detection of sex differences in the response to intravenous or intra-arterial thrombolysis, with controversial results. A pooled analysis of some randomized clinical trials on intravenous thrombolysis with tissue-type plasminogen activator (tPA) reported no difference in outcomes between men and women among those treated. Hence, the authors suggested that thrombolysis could reverse the sex differences usually observed in the spontaneous evolution of an ischemic stroke. 6 A similar conclusion was reached in a post hoc analysis based on the Canadian Alteplase for Stroke Effectiveness Study
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(CASES) database on intravenous tPA 7 and in an analysis of Prolyse for Acute Cerebral Thromboembolism-2 (PROACT-2) study on intra-arterial thrombolysis. 8 Conversely, other studies showed a worse 3-month functional outcome in women when compared with men after intravenous tPA treatment, just like in the natural course of stroke. 9 Most of the discrepancies between the above-mentioned results could be attributed to differences in study design and populations of interest and, in some cases, to small sample sizes.
The aim of this study was to evaluate possible 3-month outcome differences between sexes in patients with acute ischemic stroke treated with intravenous tPA and registered in the large database of the Safe Implementation of Treatments in StrokeInternational Stroke Thrombolysis Register (SITS-ISTR).
Methods

Patients and Procedures
Details of the methodology, including data collection and management for SITS-ISTR and SITS-Monitoring Study (SITS-MOST), have been described previously. 10, 11 In short, the SITS-ISTR is a prospective, multinational Internet-based register for patients treated with intravenous thrombolysis after acute ischemic stroke, 11 in which the SITS-MOST cohort is embedded representing the subset of patients treated under terms of the European product license. 10 All patients registered in SITS-ISTR between December 2002 and December 2011 were included in the analysis. Most patients were compliant with European summary of product characteristics criteria, although the register also includes patients treated without a strict adhesion to some of the relative contraindications of the treatment protocol.
Patient demographic and baseline characteristics were recorded, including risk factors for stroke (arterial hypertension, diabetes mellitus, hyperlipidemia, cigarette smoking, congestive heart failure, atrial fibrillation [AF], and previous stroke), stroke severity measured by National Institutes of Health Stroke Scale (NIHSS) score, 12 blood pressure, stroke pathogenesis according to the International Statistical Classification of Diseases, Tenth Revision (ICD-10), and time intervals, such as onset-to-door time, door-to-needle time, and stroke onset-to-treatment time. NIHSS was reassessed at 2 and 24 hours and at 7 days.
All patients had a baseline computed tomography scan to determine eligibility for the treatment, and a second scan was performed 22 to 36 hours after the infusion of tPA, whereas other post-treatment imaging scans were performed if necessary. The most relevant baseline and follow-up imaging scan data have been collected in the register, including early ischemic signs and hyperdense middle cerebral artery sign. All imaging scans were used to assess hemorrhagic transformation.
The primary outcome measures were symptomatic intracerebral hemorrhage (SICH), death, and functional independence at 3 months. SICH was considered, according to SITS-MOST definition, 10 as local or remote parenchymal hemorrhage type 2 13 on the 22-to 36-hour post-treatment imaging scan, combined with a neurological deterioration of ≥4 points on the NIHSS score from baseline, or from the lowest NIHSS value between baseline and 24 hours, or leading to death.
For the death end point, information was obtained through hospital records, supported by consulting official population registers or general practitioner reports where available. Functional independence at 3 months was defined as modified Rankin Scale (mRS) score 0 to 2.
14 The score was assessed by clinical examination of the patients or from patient or family interview by phone or, in some centers, by letter reply form.
Secondary outcome measures were the proportion of patients with SICH defined, according to National Institutes of Neurological Disorders and Stroke study criteria, as any hemorrhage plus a neurological deterioration (NIHSS score, ≥1) or that leads to death within 7 days; the proportion of patients with SICH defined, according to European Cooperative Acute Stroke Study (ECASS) criteria, as any hemorrhage plus a neurological deterioration of ≥4 points on the NIHSS from baseline, or from the lowest NIHSS value after baseline to 7 days, or leading to death; and excellent functional outcome as no or minimal disability defined by mRS score 0 to 1 at 3 months. 10 The study was approved by local Ethics Committees, and patient consent was obtained in countries where required; in many countries, ethical approval and patient consent were not required for an anonymized audit of a treatment that had been approved by regulatory authorities.
Statistical Analysis
Descriptive statistics were performed by sex for demographic details and baseline characteristics. All values were presented as median (interquartile range) or mean (±SD) for continuous variables and counts (percentage) for categorical variables; percentage proportions were calculated by dividing the number of events by the total number of patients, excluding missing or unknown cases. Baseline characteristics and outcomes were compared by sex using Fisher exact test for categorical data and the Mann-Whitney U test for continuous data.
To look for sex-related differences in outcome measures, multivariate logistic regression analysis was performed by including, along with sex, variables presenting with univariate associations of P≤0.20 and those variables potentially influencing outcome measures irrespective of the univariate association, such as age, baseline NIHSS, and time interval from stroke onset to treatment. A 2-sided P<0.05 was considered statistically significant. All analyses were performed with Statistica version 10.0.
Results
For the study period from December 2002 to December 2011, 45 079 patients were included in the SITS-ISTR. Of them, 25 777 (57.2%) were men and 19 302 (42.8%) were women.
Demographic and baseline characteristics are reported by sex in Table 1 
00001).
The proportions of stroke from largevessel disease and lacunar infarct were higher among men, whereas cardioembolic stroke was more prevalent in women (37.8% versus 28.9%; P<0.0001). As regards to therapy before the index stroke, women were significantly less likely to be treated with acetylsalicylic acid (ASA; 31.5% versus 32.5%; P=0.02) but were more often treated with oral anticoagulants (2.8% versus 2.3%; P=0.0005) and antihypertensive agents (52.1% versus 46.4%; P<0.0001). We did not find any differences between sexes for the presence of definite early imaging infarct signs (20.3% versus 20.0%; P=0.33). No significant sex-related differences in the proportion of hyperdense middle cerebral artery sign detected at baseline were found ( Univariate analysis did not show differences between men and women in SICH rate according to any definition ( Table 2) . We also did not observe significant differences Figure) .
In the multivariate analysis, after adjustment for confounding variables, we did not find any differences between sexes in 3-month functional outcome (odds ratio, 1.03; 95% confidence interval, 0.97-1.09; P=0.39), whereas male sex resulted as independently associated with a higher odds ratio for SICH, according to all definitions, and mortality (odds ratio, 1.19; 95% confidence interval, 1.10-1.29; P=0.00003) ( Table 3 ).
Discussion
In this large SITS-ISTR cohort of patients receiving intravenous thrombolysis, 99% within 4.5 hours and 1% within 6 hours of ischemic stroke onset, we did not find any difference between sexes in terms of functional independence. However, male sex was related to higher mortality, although women were older, more likely to be dependent before the index stroke, had a higher prevalence of hypertension and AF in the medical history, and a higher median NIHSS at stroke onset.
Our results on functional outcome are in agreement with those of a pooled analysis of randomized clinical trials on intravenous tPA (National Institutes of Neurological Disorders and Stroke, Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke [ATLANTIS] A and B, ECASS II), 6 which reported no difference between men and women in 90-day mRS ≤1, after controlling for potential imbalances, including older age and higher prevalence of hypertension in women. Moreover, in that analysis a 10% relative benefit in functional outcome in women receiving tPA in comparison with those receiving placebo (40.5% versus 30.3%; P<0.001) was detected, whereas no significant difference was found between treated and control men (38.5% versus 36.7%; P=0.52), suggesting that intravenous thrombolysis may nullify the sex differences in spontaneous clinical evolution after stroke. Our data are also in agreement with those of the large multicenter, open-label CASES, 7 in which despite older age and higher prevalence of hypertension and AF in women, no significant differences between sexes were found in 90-day functional outcome after adjustment for confounding variables. But, at variance with our study, authors did not observe any sex differences for mortality. Results similar to ours were observed in smaller open-label studies on intravenous tPA, [15] [16] [17] [18] as well as in a systematic review of 16 studies on intravenous thrombolysis, which reported no sex-based difference in functional outcome after controlling for the typical baseline imbalances between men and women. 18 Randomized clinical trials on intra-arterial thrombolysis, such as PROACT-2, 8 reached the same conclusion as that of the intravenous thrombolysis randomized clinical trial pooled analysis, 6 with regard to a similar functional outcome between sexes, with a 20% relative benefit in women and 10% in men after treatment with intra-arterial prourokinase when compared with the respective placebo counterparts. Recanalization rates were similar between the 2 groups as well. Consistent with these results, open-label studies on intra-arterial thrombolysis with tPA or urokinase did not find any differences in short-term clinical and angiographic outcomes between men and women. 19, 20 Different from ours and other results, a secondary analysis of the Glycine Antagonist in Neuroprotection, a randomized controlled double-blind trial of gavestinel for patients with acute ischemic stroke, 9 reported that among 333 patients without upper age limits treated with intravenous tPA within 3 hours, men were ≈3× more likely to have good functional outcomes even after controlling for baseline imbalances but showed a trend toward a worse survival rate than women. The small sample of patients in the study, the potential selection bias because of the exclusion from the study of patients who rapidly responded to thrombolytic treatment, as well as the high proportion of patients with severe stroke, with a trend toward a nonsignificantly higher percentage of severe strokes in women, might account for the study results.
In the present SITS-ISTR cohort, the proportions of SICH according to the different definitions were similar in both sex groups, but in the multivariate analysis male sex was independently associated with a higher risk of SICH by any definition. A possible explanation of this result might be that men were more likely to be treated with ASA before the index stroke and weighed more than women, variables known to be related with the risk of SICH. 21, 22 Hence, although based on uncontrolled data, the results of our study seem to support the hypothesis of the reversal of sex differences in stroke natural outcome after intravenous tPA, suggesting that there might be a relatively larger benefit and greater safety for the treatment in women compared with men.
This possible sex effect on the modification of tPA treatment benefit might be at least, in part, explained by the higher prevalence among women of AF which, in the natural history of stroke, has a negative prognostic role because cardioembolic strokes are usually associated with a more severe neurological impairment and higher mortality. 1, [3] [4] [5] However, the fibrin-rich and smaller volume embolic clots, often observed in cardioembolism, might also be the reason for women to be relatively more prone to recanalization after intravenous thrombolysis and to benefit from the treatment. 17, 23 In agreement with this hypothesis, the course of the hyperdense middle cerebral artery sign during follow-up in our series would suggest a relatively more frequent occurrence of arterial recanalization in women compared with men.
This study has some limitations. First, it was a retrospective study, although on data collected and entered prospectively in the SITS-ISTR. Therefore, the possibility of under-reporting might exist, although minimal, because the participating centers have been continuously encouraged to enter all of the cases in the register, and moreover part of the data was from the SITS-MOST for which source data verification was monitored. Second, our study did not have a control group of untreated patients; hence, we may only infer that similarities in functional outcome and differences in risk of mortality and SICH between men and women are consequent to different sex-related response to the treatment. However, randomized controlled studies would not be ethically acceptable because tPA has been proven to be an effective treatment for patients with acute ischemic stroke. Moreover, because SITS-ISTR includes only patients treated with thrombolysis, we were not able to account for those baseline variables for which patients did not get intravenous tPA that would be related to sex, for example, older age, prestroke disability, or sociodemographics, and that would also be associated with poor outcomes. The strength of this study is the sample size because SITS-ISTR is the largest multicenter register on intravenous thrombolysis, allowing for highly powerful multivariable analyses and generalizability of the results.
In conclusion, data from SITS-ISTR suggest that functional outcome after intravenous thrombolysis in patients with acute ischemic stroke is similar in women and men, with a higher risk of SICH and mortality in men. Given the sexrelated difference in outcome expected in the natural course of an ischemic stroke, our results would suggest a possible larger beneficial effect of intravenous tPA in women compared with men.
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